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Abstract
Background: Anti-TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA)
independent of clinical response. This has previously not been examined for periarticular bone loss, the other
characteristic feature of bone involvement in RA.
The objective of this study was to examine if treatment with the TNF-a inhibitor adalimumab also could reduce
periarticular bone loss in RA patients independent of disease activity.
Methods: RA patients were recruited from the PREMIER study and included 214 patients treated with
methotrexate (MTX) plus adalimumab and 188 patients treated with MTX monotherapy. Periarticular bone loss was
assessed by digital X-ray radiogrammetry metacarpal cortical index (DXR-MCI). Change in DXR-MCI was evaluated
in patients with different levels of clinical response, as assessed by changes in DAS28 score at 52 weeks and in
mean C-reactive protein (CRP) levels during follow-up.
Results: In the MTX group, there was a greater median DXR-MCI loss among patients with moderate and high
disease activity compared to those in remission or with low disease activity (-3.3% vs. -2.2%, p = 0.01). In contrast,
periarticular bone loss was independent of disease activity (-1.9% vs. -2.4%, p = 0.99) in the combination group. In
the MTX group patients with a mean CRP of ≥ 10 mg/l lost significantly more DXR-MCI than patients with low CRP
(-3.1% vs. -1.9%, p <0.01) whereas in the combination group no significant differences between the two CRP
groups was seen (-2.4% vs. -2.0%, p = 0.48).
Conclusion: Adalimumab in combination with MTX reduces periarticular bone loss independently of clinical
response. These results support the hypothesis that TNF-a stimulates the osteoclast not only by the inflammatory
pathway but do also have a direct effect on the osteoclast.
Trial Registration: ClinicalTrials (NCT): NCT001195663
Background
In rheumatoid arthritis (RA), bone damage on radio-
graphs is visible as erosions and periarticular osteoporo-
sis. Substantial data support that both erosions and
osteoporosis in RA share a common cellular pathway
which involves stimulation of the osteoclast. This osteo-
clast activation depends on stimulation from receptor
activator of nuclear factor- ligand (RANKL) which
binds to the receptor activator of nuclear factor-
(RANK) on the osteoclast. The expression of RANKL is
stimulated by pro-inflammatory cytokines (i.a. TNF-a,
interleukin-1 (IL-1), IL-6 and IL-17). In addition recent
data also suggest decreased osteoblast activation through
the Wnt system [1].
In comparison to disease modifying anti-rheumatic
drugs (DMARDs) including methotrexate (MTX), anti-
TNF therapy has been shown to be superior in reducing
the rate of both radiographic joint damage [2-4] and
hand bone loss [5,6]. Recently, the rate of radiographic
joint progression was reported to be reduced indepen-
dent of a patient’s clinical response to anti-TNF therapy
[7,8]. This may suggest an additional positive effect of
anti-TNF therapy on bone in RA independent of its
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anti-inflammatory effect. This has previously not been
examined for periarticular bone loss.
The objective of this study was to examine if treat-
ment with the TNF-a inhibitor adalimumab also could
reduce periarticular bone loss in RA patients indepen-
dent of disease activity.
Methods
The PREMIER study cohort was used to examine the
relationship between periarticular bone loss and clinical
response in RA patients treated with MTX and anti
TNF-therapy.
In this cohort, radiographic joint progression has
recently been reported to be reduced independently of
patients’ clinical responses to anti-TNF therapy with
adalimumab [7].
The clinical, radiographic and bone density data from
this 2-year, multi-centre, double-blind, randomised con-
trolled study has previously been described in detail [6,9]
In short, the efficacy and safety of adalimumab plus
MTX was compared with adalimumab monotherapy and
with MTX monotherapy in 799 adult patients with early
(< 3 years, mean disease duration 9.1 month), aggressive
RA (inclusion criteria: ≥8 swollen joint; erythrocyte sedi-
mentation rate ≥28 or C-reactive protein (CRP) ≥1.5 mg/
dl; erosions or rheumatoid factor positive), who pre-
viously had not been treated with MTX [9].
Digital X-ray radiogrammetry (DXR) (Sectra,
Linköping, Sweden) was used to measure hand metacar-
pal cortical index (MCI) on the same digitised hand X-
rays used for assessment of radiographic joint damage.
DXR-MCI is defined as the combined cortical thickness
divided by the bone width and is a relative bone mea-
sure independent of bone size and bone length [10,11].
In the literature short-time in-vivo precision (CV%) has
been reported to range from 0.31-0.64% for DXR-MCI
[10,12,13].
DXR-BMD (def: cxVPAcombx(1-p), where c is a density
constant, VPA is volume per area, and p is porosity)
was intended to be the main outcome measure in this
study. However, many radiographs could not be ana-
lysed for BMD because of unknown image resolution.
The equation for DXR-BMD is based on volume per
area and requires a known resolution. Thus, DXR-MCI,
which is a relative measure less dependent of image
resolution, was used as the primary outcome measure
[6]. DXR-MCI has been shown to be highly correlated
with hand bone mineral density, both measured as DXA
hand and DXR-BMD [14]. Detailed information on the
DXR-MCI measurement of the PREMIER RA cohort
has previously been reported [6].
This sub analysis involved 188 patients from the MTX
group and 214 patients from the combination group
with available DXR data and disease activity measured
by DAS28 at 52 weeks [15]. The combination group
received adalimumab 40 mg subcutaneously every other
week plus weekly oral MTX (rapidly increased to
20 mg/week), and the monotherapy group received
weekly oral MTX plus placebo injections.
Disease activity was assessed by the disease activity
score using a 28 joint count (DAS28) at 52 weeks.
Levels achieved for DAS28 scores were stratified accord-
ing to the EULAR improvement criteria [16] for remis-
sion (DAS28 ≤ 2.60), low disease activity (DAS28
2.61-3.20), moderate disease activity (DAS28 3.21-5.10),
and high disease activity (DAS28> 5.10).
DXR-MCI bone loss at 52 weeks follow- up were
compared for patients in remission and low disease
activity vs. moderate and high disease activity according
to treatment groups, as well as for patients in remission,
low, moderate and high disease activity.
DXR-MCI loss dependent on inflammation, assessed by
CRP during follow-up, was also analysed according to
treatment groups. Mean CRP was calculated from values
at baseline, 26 weeks and 52 weeks follow-up, and a
mean CRP of <10 was defined as low inflammation.
Statistics
Since the data were skewed, non-parametric analyses
were conducted. No imputations were performed. Base-
line values were compared between treatment groups
with the Mann-Whitney method for continuous vari-
ables and the chi-squared method for categorical vari-
ables. DXR-MCI loss is described as negative values.
Group analyses were performed with the Mann-Whitney
method for two independent samples and Kruskall-
Wallis for more than two independent samples. Spear-
man correlation analyses were conducted in an attempt
to correlate changes in DXR-MCI with disease activity
measured by DAS28. Analyses that came out with a
p-value ≤ 0.05 were considered as statically significant.
Study ethics
The PREMIER study was approved a central institu-
tional review board or independent ethics committee at
each participating site approved the study, and all
patients provided written informed consent [9].
Results
Baseline characteristics are shown in Table 1. There
were no statistically significant differences between the
MTX and the combination group.
DXR MCI loss and DAS28 level
In the MTX group there were a significantly greater
DXR-MCI loss in the patients with elevated disease
activity as assessed by DAS28 than patients in remission
and low disease activity, median (interquartile range)
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(-3.3% (-6.0% to -1.4%) vs. -2.2% (-4.4% to -0.7%), p =
0.01). In the combination group there were no differ-
ences in DXR-MCI loss between patients with moderate
and high disease activity vs. patient in remission or with
low disease activity (-1.9% (-4.7% to -0.7%) vs. -2.4%
(-4.1 to -0.5%), p = 0.99), and the levels of loss were
closer to those observed for patients in the MTX group
in remission (Figure 1).
Among the patients in remission or with low disease
activity there were no difference between median DXR-
MCI loss according to treatment groups (-2.4% in the com-
bination group and -2.2% in the MTX group, p = 0.88). In
the group who still had active disease, there was signifi-
cantly greater median loss in the MTX group (-3.3% vs.
-1.9%, p = 0.02) as compared to the combination group.
The DXR-MCI loss across subgroups in remission or
with low, moderate and high disease activity is shown in
Table 2. Among RA patients receiving MTX + adalimu-
mab the bone loss was similar across the DAS28 sub-
groups (p = 0.97). For the MTX group there was a
trend that the patients with high disease activity lost
more DXR-MCI than patients with low disease activity
(p = 0.10). The correlation (correlation coefficient r)
between DAS28 and percentage DXR-MCI change was
-0.14 (p = 0.06) in the MTX group and -0.07 (p = 0.33)
for the combination group.
DXR MCI loss and CRP level
In the MTX group 184 patients had CRP measures at
baseline, 26 and 52 weeks and in the combination group
the number was 206. In the MTX group there were 57
patients with mean CRP < 10 mg/L and 127 with CRP
≥10 mg/L. In the combination group the respective
values were 86 and 120. The median DXR-MCI loss in
the MTX group was significantly higher among patients
Table 1 Baseline characteristics for the examined early
rheumatoid arthritis patients. Results are given in mean
(± standard deviation) for continuous variables and
numbers (percentages) for categorical variables
Adalimumab +
Methotrexate
(N = 214)
Methotrexate
Monotherapy
(N = 188)
Demographic characteristics
Age (years) 51.8 (14.3) 52.6 (13.2)
Female % 152 (71.0) 137 (72.9)
Clinical characteristics
Disease duration (years) 0.7 (0.8) 0.8 (0.9)
Previously taken DMARDs % 69 (32.2) 56 (29.8)
Previously taken corticosteroids % 79 (36.9) 64 (34.0)
Tender joint count (0-66) 30.5 (14.6) 31.9 (14.3)
Swollen joint count (0-66) 21.4 (11.4) 22.5 (12.1)
C-reactive protein (mg/l) 40.2 (42.4) 40.4 (40.9)
HAQ (0-3) 1.5 (0.6) 1.5 (0.7)
DAS28 6.3 (0.9) 6.3 (0.9)
DXR-MCI (mg/cm2) 0.45 (0.09) 0.45 (0.09)
DMARDs = disease modifying anti-rheumatic drugs; HAQ = Health Assessment
Questionnaire; DAS28 = 28-joint disease activity score; DXR = Digital X-ray
radiogrammetry; MCI = metacarpal cortical index.
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Figure 1 DXR-MCI loss in the methotrexate (MTX) plus adalimumab and MTX groups dependent on disease activity measured by
DAS28.
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with high CRP than low CRP (-3.1% (-6.0 to -1.4) vs.
-1.9% (-3.9 to -0.2), p <0.01). In the combination group
there was no difference regarding median DXR-MCI
loss dependent on CRP level (-2.4% (-4.6% to -0.7%) vs.
-2.0% (-4.1% to 0.8%), p = 0.48), Figure 2. The patients
with high CRP treated with MTX lost significant more
DXR-MCI than patients treated with MTX and adalimu-
mab (-3.1 vs. - 2.4, p = 0.02), while there was no differ-
ence in bone loss in patient with low CRP (- 1.9 vs. -2.0,
p = 0.78).
Discussion
The main finding in this study was that adalimumab in
combination with MTX reduces hand bone loss
independently of clinically assessed disease activity. This
has previously been shown for radiographic joint
damage [7,8], but the present study is the first to show
this for hand bone loss. This disconnection between
inflammation and bone loss was not seen in MTX-
treated patient. Patients with a poor clinical response or
elevated CRP are at high risk of developing bone
damage when treated with MTX monotherapy, while
the bone will be protected independent of clinical
response among users of MTX in combination with
anti-TNF-a therapy.
These results support the hypothesis that TNF-a can
influence bone loss not only by stimulating RANKL by
inflammation. The most probable additive mechanism is
Table 2 DXR-MCI loss in the methotrexate plus adalimumab group and the MTX group stratified for disease activity
measured by DAS28
Adalimumab + methotrexate Methotrexate
N = 214 Median (mean) % DXR-MCI change N = 188 Median (mean) % DXR-MCI change
Remission
DAS28 ≤2.60
118 -2.43 (-2.73) 53 -2.15 (-3.03)
Low
disease activity
DAS28 2.61-3.20
36 -1.98 (-2.59) 30 -2.09 (-2.90)
Moderate
disease activity
DAS 28 3.21-5.10
51 -2.01 (-3.17) 81 -3.33 (-4.65)
High
disease activity
DAS28> 5.10
9 -1.63 (-2.72) 24 -3.02 (-4.64)
DAS28 = 28-joint disease activity score; DXR = Digital X-ray radiogrammetry; MCI = metacarpal cortical index.
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Figure 2 DXR-MCI loss in the methotrexate (MTX) plus adalimumab and MTX groups according to CRP level achieved.
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that TNF-a activates the osteoclast directly by binding
to osteoclasts precursors through TNF-a receptor.
Blocking of this receptor will down regulate the osteo-
clast formation [1,17]. Another theoretical mechanism
of TNF-a could be inflammation independent stimula-
tion of RANKL, however this has not yet been clinically
proven. The fact that TNF-a does have more than one
way of stimulating the osteoclast may explain the posi-
tive effect on bone despite any clinical improvement
[7,8].
Despite that bone loss was independent of disease
activity in the combination group, there were still a
bone loss observed. This loss may have been a result of
the patient selection in the PREMIER study. The
included patients had high disease activity and poor
prognosis in terms of bone damage as Rheumatoid Fac-
tor-positive and erosive disease [9,18].
This is a retrospective study and we did not have any
influence on the technical conditions regarding the
radiographs. Due to difficulties analysing DXR-BMD the
relative measure DXR-MCI was used, as described in
detail previously [6]. However, DXR has improved the
precision of MCI, and there is a strong correlation
between DXR-BMD and DXR-MCI (r > 0.9) [6,14].
Another limitation was our inability to retrieve informa-
tion on the use of bisphosphonates. This may be of
importance as treatment with bisphosphonates increases
DXR bone density [19].
Conclusion
We conclude that adalimumab in combination with
MTX reduces hand bone loss independent of disease
activity. This study highlights the bone protecting effect
of anti-TNF-a therapy.
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